Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Buprenorphine; Cannabidiol; Epidiolex

Criteria

Inclusion Criteria:

• Diagnosis of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) opioid use disorder, severe

• Currently in treatment with methadone or buprenorphine

Exclusion Criteria:

• Requiring level of care higher than outpatient treatment for alcohol, sedative/hypnotics, or stimulants

• Any current mood episode requiring level of care higher than outpatient treatment

• History of psychotic disorder or bipolar disorder

• Currently pregnant

• Hepatic liver enzymes greater than 3x upper normal limit

• Hypersensitivity to cannabinoids or sesame oil (cannabidiol solution comes in sesame oil emulsion)

• Currently taking any medications with known significant pharmacokinetic interactions with CBD